欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2003, Vol. 8 ›› Issue (1): 92-94.

• 研究原著 • 上一篇    下一篇

头孢比肟和头孢他啶治疗中重度下呼吸道感染的临床疗效及安全性评价

蒋静涵, 王莹1   

  1. 皖南医学院弋矶山医院急诊内科, 1呼吸内科, 芜湖 241001, 安徽
  • 收稿日期:2002-07-02 修回日期:2002-08-14 发布日期:2020-11-25
  • 通讯作者: 蒋静涵, 男, 副主任医师, 主要从事感染性疾病的临床研究。Tel:0553-5723766

Comparison of the efficacy and safety between cefepime and ceftazidme in the treatment of the moderate to severe low-respiratory tract infection

JIANG Jing-Han, WANG Ying1   

  1. Department of Emergency,; 1Department of Respiration, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui
  • Received:2002-07-02 Revised:2002-08-14 Published:2020-11-25

摘要: 目的: 比较头孢比肟和头孢他啶治疗中、重度下呼吸道感染的临床疗效及安全性评价。方法: 中重度下呼吸道感染患者60 例, 随机分为头孢比肟组和头孢他啶组各30 例。头孢比肟组用粉针剂1.0g 瓶。头孢他啶用粉针剂1.0 g 瓶。剂量均为:中度感染头孢比肟1.0 g, 2 次/d, 重度感染2.0 g, 2 次d, 疗程7~10 d, 个别病例延长至14 d。结果: 头孢比肟组和头孢他啶组的临床治愈率分别为73.3 %和66.7 %, 临床有效率分别为96.7 %和86.7 %, 细菌清除率分别为92.8 %和88.0 %, 药物不良反应发生率分别为3.3 %和6.7 %。头孢比肟作用优于头孢他啶, 但两者的差别均无统计学意义(P >0.05)。结论: 头孢比肟是一种治疗中重度下呼吸道感染临床疗效好、不良反应少而轻微、安全的抗生素。

关键词: 头孢比肟, 头孢他啶, 疗效, 安全性

Abstract: AIM: To compare the efficacy and safety between cefepime and ceftazidme in the treatment of the moderate to severe low-respiratory tract infection. METHODS: Sixty patients with moderate to severe lowrespiratory were enrolled in two groups.30 patents were treated with ceftzidem and other patients were given cefepine as a control.The dosage of both drugs was 1 -2 g (1 g for moderate infection, 2g for severe infection). The duration of treatment was 7 -10 d for most patients in the two groups. RESULTS: The efficacy rates of cefepime and ceftazidme were 96.67 %and 86.67 %, respectively, whereas the bacterial efficacy rates were 92.28 % and 88.0 %(P >0.05).The adverse reactions in two groups were mild and the incidence were not statistical difference between two groups (P >0.05). CONCLUSION: Cefepime is a safe and effective agent in treatment of low-respiratory tract infection like ceftazidme.

Key words: cefepime, ceftazidme, efficacy, safety

中图分类号: